Literature DB >> 18698161

Hacking hexokinase halts tumor growth.

Yongjun Fan1, Wei-Xing Zong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18698161      PMCID： PMC3140956          DOI： 10.4161/cbt.7.7.6536

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  23 in total

1.  [Expression of hexokinase-II gene in human colon cancer cells and the therapeutic significance of inhibition thereof].

Authors:  Qiu-ping Peng; Hou-jie Liang; Qi Zhou; Jin-ming Zhou; Xiao-lan Fu; Da-ping Zhong
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-04-17

Review 2.  Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt.

Authors:  R B Robey; N Hay
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

3.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.

Authors:  Valeria R Fantin; Julie St-Pierre; Philip Leder
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

Review 4.  siRNA-based approaches in cancer therapy.

Authors:  G R Devi
Journal:  Cancer Gene Ther       Date:  2006-01-20       Impact factor: 5.987

5.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.

Authors:  Rui-Hua Xu; Helene Pelicano; Yan Zhou; Jennifer S Carew; Li Feng; Kapil N Bhalla; Michael J Keating; Peng Huang
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

6.  Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells.

Authors:  Shohei Kumagai; Ritsuko Narasaki; Keiji Hasumi
Journal:  Biochem Biophys Res Commun       Date:  2007-11-13       Impact factor: 3.575

Review 7.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

8.  Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.

Authors:  Won Kim; Jung-Hwan Yoon; Jae-Min Jeong; Gi-Jeong Cheon; Tae-Sup Lee; Jong-In Yang; Su-Cheol Park; Hyo-Suk Lee
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

9.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.

Authors:  Brian Clem; Sucheta Telang; Amy Clem; Abdullah Yalcin; Jason Meier; Alan Simmons; Mary Ann Rasku; Sengodagounder Arumugam; William L Dean; John Eaton; Andrew Lane; John O Trent; Jason Chesney
Journal:  Mol Cancer Ther       Date:  2008-01       Impact factor: 6.261

Review 10.  Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells.

Authors:  Metin Kurtoglu; Johnathan C Maher; Theodore J Lampidis
Journal:  Antioxid Redox Signal       Date:  2007-09       Impact factor: 8.401
View more
  2 in total

1.  Novel predictive biomarkers for cervical cancer prognosis.

Authors:  Pablo Moreno-Acosta; Schyrly Carrillo; Oscar Gamboa; Alfredo Romero-Rojas; Jinneth Acosta; Monica Molano; Joseph Balart-Serra; Martha Cotes; Chloé Rancoule; Nicolas Magné
Journal:  Mol Clin Oncol       Date:  2016-10-19

2.  Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.

Authors:  Zhiyu Wang; Neng Wang; Jianping Chen; Jiangang Shen
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.